ArticleJournal of neurology2025
Comparative analysis of new-onset refractory status epilepticus in adult and pediatric patients: immunotherapy timing and functional outcomes.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ketogenic Diet Therapy for Adult Febrile Infection-Related Epilepsy Syndrome (FIRES): A Case Series of Five Patients and Clinical Efficacy Analysis.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to compare the clinical course of adult and pediatric patients with new-onset refractory status epilepticus (NORSE), including study of the timing of initiation of immunotherapy timing, duration of intensive care unit (ICU) stay, and functional outcomes.
methodsA retrospective review was conducted of patients with NORSE admitted to McGill University Health Centre (January 2013-July 2023). Data collected included demographics, diagnostics, treatments, ICU stay length, long-term anti-seizure medication use, and modified Rankin Scale (mRS) scores, with good outcomes defined as mRS 0-2 and poor outcomes as 3-6. Early initiation of immunotherapy was defined as administration of first-line agent within 7 days of admission and second line agent within 30 days. Comparisons were made between adult and pediatric patients.
results15 patients were identified (10 adult, 5 pediatric) with median ages of 34 and 4 years, respectively. A causative etiology was identified in three adult patients (two anti-NMDA receptor encephalitis, one small cell lung cancer) and two pediatric patients (one anti-NMDA receptor encephalitis and one hemophagocytic lymphohistiocytosis); the remainder were considered to have cryptogenic NORSE. Good functional outcomes (mRS 0-2) were seen in 80% of the pediatric cohort but only 40% of adults. Children that had earlier escalation of chronic immunosuppression tended to have better functional outcomes, though the same trend was not seen in the adult cohort. DISCUSSION: There are likely differences in presentation and clinical course between adult and pediatric patients with NORSE, with children possibly having a better long-term prognosis; however, further study is needed. Investigation into age-specific factors may guide more targeted therapeutic approaches. Ideally, a prospective multicenter randomized controlled trial would be conducted in order to generate more robust data to help determine optimal treatment protocols for NORSE across all age groups.
Indexed as
Identifiers
40251332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.